Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
Karen Barnard1,2, Mary Elizabeth Cox1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, U...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6927147c9be3449c808246b19776356e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6927147c9be3449c808246b19776356e |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:6927147c9be3449c808246b19776356e2021-12-02T01:30:14ZClinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes1178-7007https://doaj.org/article/6927147c9be3449c808246b19776356e2010-10-01T00:00:00Zhttp://www.dovepress.com/clinical-utility-of-fixed-combinations-of-sitagliptinndashmetformin-in-a5548https://doaj.org/toc/1178-7007Karen Barnard1,2, Mary Elizabeth Cox1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, USAAbstract: Adequate glycemic control in type 2 diabetes remains a difficult but achievable goal. The development of new classes of glucose-lowering medications, including in particular the incretin-based therapies, provides an opportunity to utilize combinations of medications which target multiple physiologic abnormalities in type 2 diabetes. Complementary combination therapy with sitagliptin–metformin lowers glucose via enhancement of insulin secretion, suppression of glucagon secretion, and insulin sensitization. Use of this combination in diabetes management will provide a greater degree of glycosylated hemoglobin-lowering than that seen with the use of either drug as monotherapy, is unlikely to cause significant hypoglycemia, and is generally associated with weight loss. The effectiveness, tolerability, and potential cost savings associated with the use of sitagliptin–metformin combination therapy make this an attractive option in diabetes management. The possible beneficial effects of this therapy on beta cell function, as well as its cardiovascular impact, remain inadequately explored but are of significant interest.Keywords: diabetes mellitus, sitagliptin, dipeptidyl peptidase-4, combination therapy Karen BarnardMary Elizabeth CoxJennifer B GreenDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2010, Iss default, Pp 363-372 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Specialties of internal medicine RC581-951 |
| spellingShingle |
Specialties of internal medicine RC581-951 Karen Barnard Mary Elizabeth Cox Jennifer B Green Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes |
| description |
Karen Barnard1,2, Mary Elizabeth Cox1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, USAAbstract: Adequate glycemic control in type 2 diabetes remains a difficult but achievable goal. The development of new classes of glucose-lowering medications, including in particular the incretin-based therapies, provides an opportunity to utilize combinations of medications which target multiple physiologic abnormalities in type 2 diabetes. Complementary combination therapy with sitagliptin–metformin lowers glucose via enhancement of insulin secretion, suppression of glucagon secretion, and insulin sensitization. Use of this combination in diabetes management will provide a greater degree of glycosylated hemoglobin-lowering than that seen with the use of either drug as monotherapy, is unlikely to cause significant hypoglycemia, and is generally associated with weight loss. The effectiveness, tolerability, and potential cost savings associated with the use of sitagliptin–metformin combination therapy make this an attractive option in diabetes management. The possible beneficial effects of this therapy on beta cell function, as well as its cardiovascular impact, remain inadequately explored but are of significant interest.Keywords: diabetes mellitus, sitagliptin, dipeptidyl peptidase-4, combination therapy |
| format |
article |
| author |
Karen Barnard Mary Elizabeth Cox Jennifer B Green |
| author_facet |
Karen Barnard Mary Elizabeth Cox Jennifer B Green |
| author_sort |
Karen Barnard |
| title |
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes |
| title_short |
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes |
| title_full |
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes |
| title_fullStr |
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes |
| title_full_unstemmed |
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes |
| title_sort |
clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes |
| publisher |
Dove Medical Press |
| publishDate |
2010 |
| url |
https://doaj.org/article/6927147c9be3449c808246b19776356e |
| work_keys_str_mv |
AT karenbarnard clinicalutilityoffixedcombinationsofsitagliptinampndashmetforminintreatmentoftype2diabetes AT maryelizabethcox clinicalutilityoffixedcombinationsofsitagliptinampndashmetforminintreatmentoftype2diabetes AT jenniferbgreen clinicalutilityoffixedcombinationsofsitagliptinampndashmetforminintreatmentoftype2diabetes |
| _version_ |
1718403020396429312 |